{"id":11801,"date":"2025-09-17T11:52:47","date_gmt":"2025-09-17T09:52:47","guid":{"rendered":"https:\/\/www.ebma-europe.com\/ebma\/research\/"},"modified":"2026-02-27T10:27:19","modified_gmt":"2026-02-27T09:27:19","slug":"research","status":"publish","type":"page","link":"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/","title":{"rendered":"Research"},"content":{"rendered":"\n
\n
<\/span>
\n\t
\n\t\t\n\n\t
    \n\t\t\t\t\t
  1. \n\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\tHome\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t<\/ol>\n\n\t<\/nav>\t<\/div>\n\n\n

    \n\tResearch<\/h1>\n\n\n\n

    EBMA’s research department, under the direction of Dr. Narges BAHI, conducts scientific evaluation programs for BI(G)MED. To achieve this, it focuses on 3 key areas. <\/p>\n<\/div><\/div>\n<\/div>\n\n

    \n
    \n

    1. Characterization of Ultra-Low Dose Solutions<\/h2>\n\n\n\n

    One of our BI(G)MED products was subjected to an independent test conducted by the BION research laboratory<\/a>, specializing in the analysis of subtle influences on water.<\/p>\n\n\n\n

    The test, which measures objective parameters such as pH, conductivity, and redox potential, showed a significant effect of the formula on water structuring<\/strong>.<\/p>\n\n\n\n

    This result is important: it confirms that our preparations, designed to act through fine and biomimetic modulation, produce a measurable and reproducible signal<\/strong>, consistent with our scientific approach.<\/p>\n\n\n\n

    In other words, this test provides external validation of the ability of BI(G)MED products to transmit regulatory information, thereby supporting the relevance of our innovative approach in bio-immunogenetic medicine.<\/p>\n<\/div>\n\n\n\n

    \n
    \"\"<\/figure>\n<\/div>\n<\/div>\n\n
    \n

    2. In-Vitro Studies<\/h2>\n\n\n\n

    A number of studies, whose results have not yet been published, have been conducted to evaluate the effect of our products on cultured cells<\/strong>. They show an effect on gene expression and cell function in culture. <\/p>\n<\/div>\n\n

    \n

    3. Synthesis of Clinical Cases<\/h2>\n\n\n\n

    Thanks to the entire network of BI(G)MED therapists, we are setting up retrospective studies on patients<\/strong> who have used BI(G)MED. These studies allow us to evaluate the real effectiveness of our formulas. <\/p>\n\n\n\n

    The latest retrospective study<\/a>, published in the peer-reviewed International Journal of Scholarly Research and Reviews, focuses on patients with chronic mononucleosis (Epstein-Barr Virus (EBV) infection) characterized by the absence of anti-VCA IgM, the presence of anti-VCA IgG, and the absence of anti-EBNA IgG. This serological profile, characteristic of an incomplete immune response to EBV, shows a strong association with a number of chronic pathologies such as myalgic encephalomyelitis (chronic fatigue), certain autoimmune diseases, and even some cancers. <\/p>\n\n\n\n

    The objective of this study was to investigate the kinetics of seroconversion<\/strong> (i.e., development of anti-EBNA IgG) in patients treated with BI(G)MED.<\/p>\n\n\n\n

    The study results are conclusive: 95% of patients developed anti-EBNA IgG within an average of 7 months<\/strong> following the start of treatment, and this seroconversion was accompanied in 75% of cases by a marked improvement, or even complete disappearance, of their physical symptoms<\/strong>.<\/p>\n<\/div>\n\n

    \n
    \"clinical<\/a><\/figure>\n<\/div>\n\n
    \n
    <\/span>
    \n

    We are open to any partnership proposal to develop a randomized, double-blind clinical study on one or more of our products.<\/h2>\n\n\n\n

    If you are interested, please contact our Scientific Director, Dr. Narges BAHI. \t\t\t<\/p>\n\n\n\n

    \n
    Contact<\/a><\/div>\n<\/div>\n<\/div><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    EBMA’s research department, under the direction of Dr. Narges BAHI, conducts scientific evaluation programs for BI(G)MED.<\/p>\n","protected":false},"author":778,"featured_media":0,"parent":11797,"menu_order":10,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-11801","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nGenetic Research, Studies of BI(G)MED Therapies | EBMA Europe<\/title>\n<meta name=\"description\" content=\"Characterization of ultra-low dose solutions, in-vitro studies, and retrospective clinical case studies: the 3 pillars of our research department.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genetic Research, Studies of BI(G)MED Therapies | EBMA Europe\" \/>\n<meta property=\"og:description\" content=\"Characterization of ultra-low dose solutions, in-vitro studies, and retrospective clinical case studies: the 3 pillars of our research department.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/\" \/>\n<meta property=\"og:site_name\" content=\"EBMA Europe\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-27T09:27:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2025\/12\/bion-institut-influence-sur-leau.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2550\" \/>\n\t<meta property=\"og:image:height\" content=\"2550\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/ebma\\\/research\\\/\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/ebma\\\/research\\\/\",\"name\":\"Genetic Research, Studies of BI(G)MED Therapies | EBMA Europe\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/ebma\\\/research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/ebma\\\/research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2025\\\/12\\\/bion-institut-influence-sur-leau-300x300.jpg\",\"datePublished\":\"2025-09-17T09:52:47+00:00\",\"dateModified\":\"2026-02-27T09:27:19+00:00\",\"description\":\"Characterization of ultra-low dose solutions, in-vitro studies, and retrospective clinical case studies: the 3 pillars of our research department.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/ebma\\\/research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/ebma\\\/research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/ebma\\\/research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2025\\\/12\\\/bion-institut-influence-sur-leau-300x300.jpg\",\"contentUrl\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2025\\\/12\\\/bion-institut-influence-sur-leau-300x300.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/ebma\\\/research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/accueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EBMA\",\"item\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/ebma\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/\",\"name\":\"EBMA Europe\",\"description\":\"European Bio Immune(G)ene Medicine Association\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#organization\"},\"alternateName\":\"EBMA\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#organization\",\"name\":\"EBMA Europe\",\"alternateName\":\"EBMA\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/03\\\/enity-logo-ebma.png\",\"contentUrl\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/03\\\/enity-logo-ebma.png\",\"width\":696,\"height\":696,\"caption\":\"EBMA Europe\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/fr.linkedin.com\\\/company\\\/ebma-europe\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genetic Research, Studies of BI(G)MED Therapies | EBMA Europe","description":"Characterization of ultra-low dose solutions, in-vitro studies, and retrospective clinical case studies: the 3 pillars of our research department.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/","og_locale":"en_US","og_type":"article","og_title":"Genetic Research, Studies of BI(G)MED Therapies | EBMA Europe","og_description":"Characterization of ultra-low dose solutions, in-vitro studies, and retrospective clinical case studies: the 3 pillars of our research department.","og_url":"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/","og_site_name":"EBMA Europe","article_modified_time":"2026-02-27T09:27:19+00:00","og_image":[{"width":2550,"height":2550,"url":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2025\/12\/bion-institut-influence-sur-leau.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/","url":"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/","name":"Genetic Research, Studies of BI(G)MED Therapies | EBMA Europe","isPartOf":{"@id":"https:\/\/www.ebma-europe.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/#primaryimage"},"image":{"@id":"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2025\/12\/bion-institut-influence-sur-leau-300x300.jpg","datePublished":"2025-09-17T09:52:47+00:00","dateModified":"2026-02-27T09:27:19+00:00","description":"Characterization of ultra-low dose solutions, in-vitro studies, and retrospective clinical case studies: the 3 pillars of our research department.","breadcrumb":{"@id":"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ebma-europe.com\/en\/ebma\/research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/#primaryimage","url":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2025\/12\/bion-institut-influence-sur-leau-300x300.jpg","contentUrl":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2025\/12\/bion-institut-influence-sur-leau-300x300.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ebma-europe.com\/en\/ebma\/research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ebma-europe.com\/en\/accueil\/"},{"@type":"ListItem","position":2,"name":"EBMA","item":"https:\/\/www.ebma-europe.com\/en\/ebma\/"},{"@type":"ListItem","position":3,"name":"Research"}]},{"@type":"WebSite","@id":"https:\/\/www.ebma-europe.com\/en\/#website","url":"https:\/\/www.ebma-europe.com\/en\/","name":"EBMA Europe","description":"European Bio Immune(G)ene Medicine Association","publisher":{"@id":"https:\/\/www.ebma-europe.com\/en\/#organization"},"alternateName":"EBMA","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ebma-europe.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ebma-europe.com\/en\/#organization","name":"EBMA Europe","alternateName":"EBMA","url":"https:\/\/www.ebma-europe.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ebma-europe.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/03\/enity-logo-ebma.png","contentUrl":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/03\/enity-logo-ebma.png","width":696,"height":696,"caption":"EBMA Europe"},"image":{"@id":"https:\/\/www.ebma-europe.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/fr.linkedin.com\/company\/ebma-europe"]}]}},"_links":{"self":[{"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/pages\/11801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/users\/778"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/comments?post=11801"}],"version-history":[{"count":1,"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/pages\/11801\/revisions"}],"predecessor-version":[{"id":11802,"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/pages\/11801\/revisions\/11802"}],"up":[{"embeddable":true,"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/pages\/11797"}],"wp:attachment":[{"href":"https:\/\/www.ebma-europe.com\/en\/wp-json\/wp\/v2\/media?parent=11801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}